Skip to Main Content

Diabetes Mellitus

Dapagliflozin reduced the risk of end-stage kidney disease or death from renal and cardiovascular causes in a 2020 multinational study of 4304 patients with chronic kidney disease.

The drug was safe and beneficial in patients with eGFR as low as 25 mL/min/1.73 m2.

A third of the patients in the study did not have diabetes and had benefit.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.